MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens

Citations Over TimeTop 1% of 2025 papers

Abstract

We developed a practical framework to construct digital twins for predicting and optimizing triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy (NAC). This study employed 105 TNBC patients from the ARTEMIS trial (NCT02276443, registered on 10/21/2014) who received Adriamycin/Cytoxan (A/C)-Taxol (T). Digital twins were established by calibrating a biology-based mathematical model to patient-specific MRI data, which accurately predicted pathological complete response (pCR) with an AUC of 0.82. We then used each patient's twin to theoretically optimize outcome by identifying their optimal A/C-T schedule from 128 options. The patient-specifically optimized treatment yielded a significant improvement in pCR rate of 20.95-24.76%. Retrospective validation was conducted by virtually treating the twins with AC-T schedules from historical trials and obtaining identical observations on outcomes: bi-weekly A/C-T outperforms tri-weekly A/C-T, and weekly/bi-weekly T outperforms tri-weekly T. This proof-of-principle study demonstrates that our digital twin framework provides a practical methodology to identify patient-specific TNBC treatment schedules.

Related Papers

• → Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy(2016)17 cited
• → Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer(2018)3 cited
• Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.(2016)
• [Infiltrating tumors of the bladder. Local response to systemic platinum-based chemotherapy].(1989)
• → Residual cancer cells after apparent complete pathological response to neoadjuvant therapy in oesophageal adenocarcinoma(2024)